{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-030839","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.421674+00:00","generated_at":"2026-05-23T23:49:38.768824+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest","bullets":["Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.","NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.","No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.","Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-030839","json":"https://secwatch.observer/filing/0001104659-25-030839.json","markdown":"https://secwatch.observer/filing/0001104659-25-030839.md","text":"https://secwatch.observer/filing/0001104659-25-030839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/0001104659-25-030839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:49:38.768824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}